Patents by Inventor Frank Büttner

Frank Büttner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Detection of NO by using guanylyl cyclase and cGMP production as a readout system
    Publication number: 20050112717
    Abstract: The present invention relates to a method for determining NO enzymatically and its use for the identification of substances which can modulate a nitric oxide synthase activity.
    Type: Application
    Filed: November 19, 2004
    Publication date: May 26, 2005
    Applicant: Boehringer Ingelheim International GmbH
    Inventor: Frank Buettner
  • New medicaments for the treatment of chronic obstructive pulmonary disease
    Publication number: 20040147513
    Abstract: A pharmaceutical composition comprising a compound of formula 1 1
    Type: Application
    Filed: November 10, 2003
    Publication date: July 29, 2004
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Ingo Konetzki, Kurt Schromm, Hermann Schollenberger, Sabine Pestel, Andreas Schnapp, Thierry Bouyssou, Frank Buettner, Claudia Heine, Philipp Lustenberger, Christoph Hoenke, Klaus Rudolf
  • Dihydroxymethylphenyl derivatives, processes for preparing them, and their use as pharmaceuticals
    Publication number: 20040138307
    Abstract: A compound of formula 1 1
    Type: Application
    Filed: October 30, 2003
    Publication date: July 15, 2004
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Ingo Konetzki, Kurt Schromm, Hermann Schollenberger, Sabine Pestel, Andreas Schnapp, Thierry Bouyssou, Frank Buettner, Claudia Heine
  • Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions
    Publication number: 20040122108
    Abstract: A compound of formula 1 1
    Type: Application
    Filed: September 19, 2003
    Publication date: June 24, 2004
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Frank Buettner, Ingo Konetzki, Kurt Schromm, Hermann Schollenberger, Sabine Pestel, Andreas Schnapp, Thierry Bouyssou, Claudia Heine
  • Sulfonylaminophosphinic and sulfonylaminophosphonic acid derivatives, methods for their preparation and use
    Patent number: 6500811
    Abstract: Compounds of the formula I are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading enzymes is involved.
    Type: Grant
    Filed: March 20, 2001
    Date of Patent: December 31, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Manfred Schudok, Wilfried Schwab, Gerhard Zoller, Eckart Bartnik, Frank Büttner, Klaus-Ulrich Weithmann
  • Sulfonylaminophosphinic and sulfonylaminophosphinic acid derivatives, methods for their preparation and use
    Patent number: 6235727
    Abstract: Compounds of the formula I are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading enzymes is involved.
    Type: Grant
    Filed: July 15, 1999
    Date of Patent: May 22, 2001
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Manfred Schudok, Wilfried Schwab, Gerhard Zoller, Eckart Bartnik, Frank Büttner, Klaus-Ulrich Weithmann
  • Artificial recombinant substrate (rAGG 1) and native aggrecan to determine the proteolytic activity of ‘aggrecanase’ in cell culture systems
    Patent number: 6180334
    Abstract: The invention relates to novel recombinant substrates for aggrecanase. In one embodiment, this substrate comprises the signal sequence of CD5, the FLAG-epitope for M1 monoclonal antibody detection, the interglobular domain of human aggrecan, the hinge region of human IgG1, the CH2 region of human IgG1 and the CH3 region of human IgG1. DNA sequences encoding the recombinant substrate are also provided, as are vectors and host cells containing said DNA. Various methods are provided for: monitoring aggrecanase activity, detecting new enzymatic cleavage sites, purifying aggrecanase chromatographically, and cloning the aggrecanase cDNA, screening for aggrecanase inhibitors; and for monitoring the onset or progression of osteoarthritis. A diagnostic aid containing the recombinant substrate is also provided.
    Type: Grant
    Filed: October 21, 1998
    Date of Patent: January 30, 2001
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Eckart Bartnik, Bernd Eidenmueller, Frank Buettner, Bruce Caterson, Clare Hughes
  • Artificial recombinant substrate (rAGG 1) and native aggrecan to determine the proteolytic activity of `aggrecanase` in cell culture systems
    Patent number: 5872209
    Abstract: The invention relates to novel recombinant substrates for aggrecanase. In one embodiment, this substrate comprises the signal sequence of CD5, the FLAG-epitope for M1 monoclonal antibody detection, the interglobular domain of human aggrecan, the hinge region of human IgG1, the CH2 region of human IgG1 and the CH3 region of human IgG1. DNA sequences encoding the recombinant substrate are also provided, as are vectors and host cells containing said DNA. Various methods are provided for: monitoring aggrecanase activity, detecting new enzymatic cleavage sites, purifying aggrecanase chromatographically, and cloning the aggrecanase cDNA, screening for aggrecanase inhibitors; and for monitoring the onset or progression of osteoarthritis. A diagnostic aid containing the recombinant substrate is also provided.
    Type: Grant
    Filed: January 17, 1997
    Date of Patent: February 16, 1999
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Eckart Bartnik, Bernd Eidenmueller, Frank Buettner, Bruce Caterson, Clare Hughes